Alcohol Septal Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Seven-Year Experience

Diagnosis and Management of Hypertrophic Cardiomyopathy

Volumn , Issue , 2007, Pages 279-296

  Kuhn, Horst ^a   Lawrenz, Thorsten ^a   Lieder, Frank ^a   Gietzen, Frank H ^a   Obergassel, Ludger ^a   Strunk Muller, Claudia ^a   Stolle, Berit ^a   Leuner, Christian H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Alcohol septal ablation; Hypertrophic obstructive cardiomyopathy; Non surgical septal reduction therapy; Percutaneous septal myocardial ablation; Transcoronary ablation of septal hypertrophy

Indexed keywords

EID: 84955687033     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987469.ch19     Document Type: Chapter

References (71)

1. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: Studies to develop a new catheter-based concept of treatment. Eur Heart J 1997; 18: 846-51.
2. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Abnahme der Obstruktion bei hypertro-phischer Kardiomyopathie während passagerer Okklusion des ersten Septalastes der linken Koronararterie [abstract]. Z Kardiol 1994; 83 (Suppl. 1): 146.
3. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-14.
4. Kuhn H. Transkoronare Ablation der Septum-Hypertrophie (TASH). Bericht über das 1 Bielefelder Werkstattgespräch. Z Kardiol 1998; 87: 244-8.
5. Braunwald E. A new treatment for hypertrophic cardiomyopathy? Eur Heart J 1997; 18: 709-10.
6. Kuhn H, Gietzen FH, Leuner CH et al. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000; 89, 4: 41-54.
7. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): A 5-year experience. Z Kardiol 2000; 89: 559-64.
8. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardio-myopathy. Lancet 2000; 355: 425-6.
9. Gregorini L, Marco J, Farah B et al. Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation 2002; 106: 2901-7.
10. Kuhn H, Seggewiss H, Gietzen F et al. Catheter interventional therapy for hypertrophic obstructive cardiomyopathy: First two year analysis of the national registry of the German Cardiac Society [abstract]. Eur Heart J Abstr Suppl 2000; 21: 413.
11. Kuhn H, Gietzen F, Schäfers M et al. Changes of left ventricular outflow tract after transcoronary ablation of septum hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transesophageal echocardiography and measuring of myocardial glucose utilization and perfusion. Eur Heart J 1999; 20: 1808-17.
12. Boekstegers P, Steinbigler P, Molnar A et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 846-53.
13. Kuhn H, Lawrenz T, Gietzen F, Obergassel L, Lieder F, Leuner C. Catheter based treat-ment for HOCM: Technique, complications and prognosis. J Heart Fail Abstr 2002; 7: 16.
14. Gietzen FH, Leuner CJ, Raute-Kreinsen U et al. Acute and long-term results after trans-coronary ablation of septum hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999; 20: 1342-54.
15. Kuhn H, Gietzen F, Lerch M, Lieder F, Meyer zu Vilsendorf D, Kruse J. The impact of ex-ercise Doppler echocardiography in patients treated by transcoronary ablation of septal hypertrophy [abstract]. Eur Heart J Abstr Suppl 2000; 21: 113.
16. Beer G, Strunk-Müller C, Gietzen FH, Kuhn H. Discrete subvalvular aortic stenosis (DSAS) - pitfall in the diagnosis of patients with hypertrophic obstructive cardiomyopathy (HOCM). Eur Heart J Abstr Suppl 2002; 23: 313.
17. Lakkis NM, Nagueh SF, Kleiman NS et al. Echocardiography-guided ethanol septal re-duction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 1750-5.
18. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-21.
19. Klues HG, Leuner C, Kuhn H. Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: Increase in gradient after exercise. J Am Coll Cardiol 1992; 19: 527-33.
20. Ruzyllo W, Chojnowska L, Demkow M et al. Left ventricular outflow tract decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000; 21: 770-7.
21. Seggewiss H, Gleichmann U, Faber L, Fassebender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three months follow up in 25 patients. J Am Coll Cardiol 1998; 31: 252-8.
22. Krater L, Seggewiss H, Meissner A, Faber L, Horstkotte B. Long-term clinical and he-modynamic outcome after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 37: 203A.
23. Kim JJ, Lee CW, Park SW et al. Improvement in exercise capacity and exercise blood pressure responds after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1999; 83: 1220-3.
24. Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG. The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hyper-trophic obstructive cardiomyopathy after septal artery embolization. Circulation 2000; 18: 1764-6.
25. Seggewiss H, Faber L, Ziemssen P. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cardiol Rev 1999; 7: 316-23.
26. Knight C, Kurbaan AS, Seggewiss H et al. Non-surgical septum reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997; 95: 2075-81.
27. Kern MJ, Rajjoub H, Bach R. Hemodynamic round series II: Hemodynamic effects of alcohol-induced septal infarction for hypertrophic obstructive cardiomyopathy. Cath Cardiovasc Intervent 1999; 47: 221-8.
28. Omman A, Ramachandran P, Subramanyan K, Kalarickal MS, Osman MN. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results. J Invasive Cardiol 2001; 13: 526-30.
29. Spirito P, Rubartelli P. Alcohol septal ablation in the management of obstructive hyper-trophic cardiomyopathy. Ital Heart J 2000; 1: 721-5.
30. Henein MY, O'Sullivan CA, Ramzy IS, Sigwart U, Gibson DG. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34: 1117-22.
31. Mazur W, Nagueh SF, Lakkis NM et al. Regression of left ventricular hypertrophy after non surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103: 1492-6.
32. Sitges M, Kapadia S, Rubin DN, Thomas JD, Tuzcu ME, Lever HM. Percutaneous translu-minal alcohol septal myocardial ablation after aortic valve replacement. Catheter Cardio- vasc Intervent 2001; 53: 524-6.
33. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. HCM in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26: 1529-36.
34. Lakkis N, Plana JC, Nagueh S, Killip D, Roberts R, Spencer WH. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardio-myopathy and provocable gradients. Am J Cardiol 2001; 88: 583-6.
35. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH. Non surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000; 36: 852-5.
36. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Müller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, NYHA functional class III or IV and outflow obstruction only under provocable conditions. Circulation 2002; 106: 454-9.
37. Morrow AG, Reitz BA, Epstein SE et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975; 52: 88-102.
38. Maron BI, Merrill WH, Freier PA et al. Long term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 1978; 57: 1205-13.
39. Robbins RC, Stinson EB. Long term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996; 111: 586-94.
40. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardio-myopathy. Lancet 2000; 355: 425-6.
41. Beer G, Gietzen F, Gabbert HE, Lieder F, Kuhn H. Incidental diagnosis of Fabry's disease in a patient with hypertrophic obstructive cardiomyopathy not responding to catheter interventional therapy [abstract]. Eur Heart J 2001; 22: 407.
42. Lieder F, Gellerich F, Lawrenz T, Beer G, Holzhausen HJ, Kuhn H. Skeletal myopathy with fiber type I predominance and ultrastructural abnormalities in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2003; 24 (Abstr. Suppl.): 561.
43. Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H. FABRY disease in patients with hyper-trophic cardiomyopathy (HCM). Z Kardiol 2002; 91: 992-1002.
44. Lawrenz T, Gietzen F, Lieder F, Obergassel L, Kuhn H. Prognosis of patients with hyper-trophic obstructive cardiomyopathy after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J Abstr Suppl 2002; 4: 734.
45. Mogensen J, Egeblad H, Hansen PS, Jensen HK, Thysen L. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. A new therapeutic option. Ugeskr Laeger 2000; 162: 1371-5.
46. Airoldi F, Di Mario C, Catanoso A et al. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 2000; 1: 200-6.
47. Keren A, Nanai S. Transcatheter ablation of septal hypertrophy: A promising alternative to surgery in hypertrophic obstructive cardiomyopathy. Isr Med Assoc J 2002; 4: 114-16.
48. Obergassel L, Gietzen F, Strunk-Müller C et al. Does transcoronary ablation of septal hy-pertrophy (TASH) in hypertrophic obstructive cardiomyopathy (HOCM) induce an ar- rhythmogenic substrate? Clinical results and Holter-ECG-data. Pacing Clin Electrophysiol 2001; 24 (II): 694.
49. Gietzen FH, Leuner CH, Obergassel L, Strunk-Müller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy for relief of syncope in hypertrophic obstructive cardio-myopathy. Eur Heart J Abstr Suppl 2001; 22: 704.
50. Kuhn H, Gietzen F. Transcoronary ablation of septal hypertrophy (TASH): Supersedes it the surgery (myectomy)? Herz 1999; 24: 647-51.
51. Abraham TP, Nishimura RA, Holmes DR, Belohlavek M, Seward JB. Strain rate imaging for assessment of regional myocardial function. Results from a clinical model of septal ablation. Circulation 2002; 105: 1403-6.
52. Nagueh SF, Stetson SJ, Lakkis NM et al. Decreased expression of tumor necrosis factor-a and regression of hypertrophy after non surgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001; 103: 1844-50.
53. Raute-Kreinsen U. Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathol Res Pract 2003; 199: 121-7.
54. Kuhn H, Gietzen F, Leuner C. The abrupt no-flow: A no-reflow like phenomenon in hy-pertrophic cardiomyopathy. Eur Heart J 2002; 23: 91-3.
55. Wu DJ, Ueng KC, Lin CS et al. Multivessel spasm during coronary angiographic procedure in catheterization laboratory. Acta Cardiol Sin 1999; 15: 45-50.
56. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001; 22: 729-39.
57. Kuhn H, Gietzen FH, Breithardt G et al. Pacemaker therapy and alcohol ablation for HOCM: A randomized study [abstract]. Eur Heart J 2001; 22: 20.
58. Schulte HD, Bircks WH, Losse B, Godehardt EAJ, Schwartzkopff B. Prognosis of patients with HOCM after transaortic myectomy. J Thorac Cardiovasc Surg 1993; 106: 709-17.
59. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy. Long term results after surgical therapy. Thorac Cardiovasc Surg 1999; 47: 213-18.
60. Kuhn H, Krelhaus W, Bircks W, Schulte HD, Loogen F. Indication for surgical treatment in patients with hypertrophic obstructive cardiomyopathy. In: Kaltenbach M, Loogen F, Olsen EGJ, eds. Cardiomyopathy and Myocardial Biopsy. Berlin: Springer, 1978: 308-15.
61. Loogen F, Kuhn H, Gietzen F, Losse B, Schulte HD, Bircks W. Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non obstructive cardiomyopathy. Eur Heart J 1983; 4 (Suppl. F): 145-53.
62. Gadler F, Linde C, Juhlin-Dannfelt A, Ribeiro A, Ryden L. Long term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. Eur Heart J 1997; 18: 636-42.
63. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber pacing in obstructive hypertrophic cardiomyopathy. Circulation 1994; 90: 2731-42.
64. Nishimura RA, Trusty JM, Hayes DL et al. Dual-chamber pacing for hypertrophic car-diomyopathy: A randomized, double-blind, crossover trial. J Am Coll Cardiol 1997; 29: 435-41.
65. Kappenberger L, Linde C, Daubert C et al. Pacing in hypertrophic obstructive cardiomy-opathy: A randomized crossover study. PIC Study Group. Eur Heart J 1997; 18: 1249-56.
66. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assess-ment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 1999; 99: 2927-33.
67. Ommen SR, Nishimura RA, Squires RW, Shaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hy-pertrophic obstructive cardiomyopathy: A comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol 1999; 34: 191-6.
68. Maron BJ, Danielson GK, Kappenberger LJ et al. ACC/ESC Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology/ American Heart Association Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. (In press.)
69. Schulte HD, Gramsch-Zabel H, Schwartzkopff R. Hypertrophic obstructive cardiomyopathy (HOCM): Surgical management. Schweiz Med Wochenschr 1995; 125: 1940-9.
70. Mannebach H, Hamm C, Horstkotte D. 17 Bericht über die Leistungszahlen der Herz-katheterlabore in der Bundesrepublik Deutschland. Z Kardiol 2001; 90: 665-7.
71. Spencer WH 3rd, Roberts R. Alcohol septal ablation in hypertrophic obstructive cardio-myopathy: The need for a registry. Circulation 2000; 102: 600-1.